Novo Nordisk A/S (NONOF)
| Market Cap | 202.73B -23.8% |
| Revenue (ttm) | 50.57B +8.1% |
| Net Income | 18.81B +16.6% |
| EPS | 4.23 +16.8% |
| Shares Out | n/a |
| PE Ratio | 10.78 |
| Forward PE | 14.16 |
| Dividend | 1.23 (2.67%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 21,757 |
| Average Volume | 65,133 |
| Open | 46.75 |
| Previous Close | 45.37 |
| Day's Range | 45.00 - 46.96 |
| 52-Week Range | 34.00 - 82.50 |
| Beta | 0.35 |
| RSI | 69.84 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
Eli Lilly and Novo Nordisk dominate the weight loss drug market with their injectable GLP-1 drugs. Both players recently won approval for oral formulations, offering patients a new, convenient option.
Oral Ozempic and Wegovy pills now available for same-day delivery on Amazon
"This has been the best product launch in the last decade that we have seen."
Novo Nordisk (NVO) Raises 2026 View, but Adjusted Growth Tells a More Complicated Story
Novo Nordisk A/S (NVO) delivered a first-quarter report that looked impressive at first glance. Net sales reached DKK 96,823 million,... The post Novo Nordisk (NVO) Raises 2026 View, but Adjusted Grow...
Novo Nordisk Sees 40% Spike in India April Sales Despite Generic GLP-1 Rivalry
Danish drugmaker Novo Nordisk ($NVO) saw a 40% jump in the sales of its diabetes and weight-loss drugs in April in India, despite intense competition from generic GLP-1 offerings, Bloomberg
Novo Nordisk's Pricing Strategy Boosts Demand for Wegovy and Ozempic
Novo Nordisk's Pricing Strategy Boosts Demand for Wegovy and Ozempic
Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies fl...
Mixed options sentiment in Novo Nordisk with shareslittle changed
Mixed options sentiment in Novo Nordisk (NVO), with shares up 4c, or 0.1%, near $45.80. Options volume relatively light with 69k contracts traded and calls leading puts for a put/call
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential
Shares of Novo Nordisk ($NVO) and Eli Lilly & Co. ($LLY), two of the world’s largest drugmakers, rose slightly on Wednesday after data showed strong demand for their new oral
Amazon.com expands access to Ozempic pill via same-day delivery
Amazon Pharmacy (AMZN) is expanding access to Novo Nordisk’s (NVO) Ozempic pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription ...
Novo and Lilly gain on signs weight-loss pills could expand the market
Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricin...
Amazon (AMZN) Targets GLP-1 Growth with Novo’s Ozempic Pill
Amazon ($AMZN) is adding Novo Nordisk ($NVO)’s Ozempic pill to Amazon Pharmacy, as it builds a deeper role in the fast-growing market for GLP-1 drugs. The drug is used to
Amazon to carry Ozempic pill at U.S. kiosks, offer same-day delivery
Amazon said on Thursday its pharmacy will stock Novo Nordisk's Ozempic pill to treat type 2 diabetes at its kiosks and offer same-day delivery of the drug.
Amazon to carry Ozempic at US kiosks, offer same-day delivery
Amazon.com said on Thursday its pharmacy will stock Novo Nordisk's Ozempic pill to treat type 2 diabetes at its kiosks and offer same-day delivery of the drug
Novo Nordisk reports Q1 adjusted EPS DKK 6.63 vs. DKK 6.82 last year
Reports Q1 revenue DKK 96.82B vs. DKK 78.09B last year. The company said, “Wegovy is driving a strong start to 2026 for Novo Nordisk (NVO), led by the rapid adoption
Novo Nordisk raises FY26 adjusted sales view to down 4%-12% from down 5%-13%
Raises FY26 adjusted operating profit view to down 4%-12% from down 5%-13%. The company said, ” The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales.” Published
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Eli Lilly (LLY) Raises Bet to $21B as Obesity Pill War with Novo Nordisk Intensifies
U.S. pharma giant Eli Lilly ($LLY) has pumped another $4.5 billion investment into its manufacturing facilities in Indiana, a key anchor of its domestic manufacturing buildout. The figure has raised
My Top Obesity Stock to Buy and Hold
Eli Lilly's Zepbound is already generating billions of dollars in revenue, making it the clear leader in a rapidly expanding market. Lilly's ability to produce and deliver creates a hurdle that smalle...
Q1 2026 Novo Nordisk A/S Earnings Call Transcript
Q1 2026 Novo Nordisk A/S Earnings Call Transcript
Mizuho's Jared Holz: Surprised Wall Street hasn't rallied around Novo Nordisk yet
Jared Holz, Mizuho, joins 'Fast Money' with reaction to Novo Nordisk quarterly results.
Novo Nordisk's first weight loss pill smashes sales forecasts as company hails surging demand
Novo Nordisk launched its Wegovy pill in January as it fought back against Eli Lilly, the maker of rival drug Mounjaro, after seeing sales and profits tumble.
Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world
CNBC's Angelica Peebles speaks with Novo Nordisk CEO Mike Doustdar about the company's quarterly report, the strong launch of the Wegovy pill and what else Novo Nordisk has to come in the pipeline. He...